Dr. Tan’s work identified new types of lysine acyl modifications, revealed the regulatory mechanisms of PTMs in diseases (Cell 2011, Nat Chem Biol 2011, Cell Metab 2014, Nat Commun 2018), demonstrated a new therapeutic strategy by targeting the PTM crosstalks (Cell 2018) for lysine methyltransferase EZH2 inhibitors, revealed the proteomic landscape in lung cancers (Cell 2020), identified the subtypes and combination therapies of KRAS mutant cancers (Mol Cell 2021), disclosed a new mechanism of kinase  DRAK2 in nonalcoholic fatty liver disease through SRSF6-associated RNA alternative splicing (Cell Metab 2021), and characterized the global phosphorylation-dependent substrates of cullin ring ubiquitin ligases (Cell Death Differ 2021). 

2019, VCANBIO Award for Innovations and Breakthroughs in Life Sciences and Medicine

2013, Young Investigator Award of China Human Proteome Organization (CNHUPO)

1.Liu Z, Liu Y, Qian L, Jiang S, Gai X, Ye S, Chen Y, Wang X, Zhai L, Xu J, Pu C, Li J, He F, Huang M*, and Tan M*. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell, 2021, 81: 4076-4090 

2.Li Y, Xu J, Lu Y, Bian H, Yang L, Wu H, Zhang X, Zhang B, Xiong M, Chang Y, Tang J, Yang F, Zhao L, Li J, Gao X, Xia M*, Tan M*, Li J*. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metab. 2021 33: 2004–2020. 

3.Liu P, Cong X, Liao S, Jia X, Wang X, Dai W, Zhai L, Zhao L, Ji J, Ni D, Liu Z, Chen Y, Pan L, Liu W, Zhang J, Huang M, Liu B*, Tan M*. Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis. Cell Death Differ, 2021 DOI: 10.1038/s41418-021-00827-7 

4.Xu J, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, Qian K, Sun C, Liu Z, Jiang S, Wang M, Feng L, Zhao L, Liu P, Wang B, Zhao X, Xie H, Yang X, Zhao L, Chang Y, Jia J, Wang X, Zhang Y, Wang Y, Yang Y, Wu Z, Yang L, Liu B, Zhao T, Ren S, Sun A, Zhao Y, Ying W, Wang F, Wang G, Zhang Y, Cheng S, Qin J, Qian X, Wang Y*, Li J*, He F*, Xiao T*, Tan M*. Integrative proteomic characterization of human lung adenocarcinoma. 2020 Cell 182: 245-261

5.Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng XL, Liu Z, Zhang X, Yang H, Hao B, Shen Y, Su Y, Cong X, Huang M, Tan M*, Ding J*, Geng M*. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell 2018，175:186-199. 

6.Liu B, Jiang S, Li M, Xiong X, Zhu M, Li D, Zhao L, Qian L, Zhai L, Li J, Lu H, Sun S, Lin J, Lu Y *, Li X*, Tan M*. Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis. Nat Commun 2018, 9: 4770 

7.Hu H, Zhao W, Zhu M, Zhao L, Zhai L, Xu JY, Liu P, Tan M*. LysargiNase and Chemical Derivatization Based Strategy for Facilitating In-Depth Profiling of C-Terminome. Anal Chem. 2019 91: 14522-14529

8.Tan M.#, Peng  C.#, Anderson K.A.#, Chhoy P., Xie Z., Dai L., Park J.S., Chen Y., Huang H., Zhang Y., Ro J., Wagner G.R., Green M.F., Madsen A.S., Schmiesing J., Peterson B.S., Xu G., Ilkayeva O.R., Muehlbauer M.J., Braulke T., Mühlhausen C., Backos D.S., Olsen C.A., McGuire P.J., Pletcher S.D., Lombard D.B., Hirschey M.D.*, Zhao Y*. Lysine Glutarylation Is a Protein Post-Translational Modification Regulated by SIRT5. Cell Metab 2014,19: 605-617

9.Tan M.#, Luo H.#, Lee S.#, Jin F., Yang J.S., Montellier E., Buchou T., Cheng Z., Rousseaux S., Rajagopal N., Lu Z., Ye Z., Zhu Q., Wysocka J., Ye Y., Khochbin S., Ren B., Zhao Y*. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146, 1016-1028

10.Zhang Z.#, Tan M.#, Xie Z., Dai L., Chen Y., Zhao Y.*. Identification of lysine succinylation as a new post-translational modification. Nat Chem Biol 2011, 7, 58-63